Financial Data and Key Metrics Changes - Revenue for Q1 was $598 million, reflecting a slight decline of 0.8% year-over-year on a constant currency basis, primarily due to softer enabling technology sales and supply chain disruptions [6][19] - Non-GAAP EPS increased by 9% to $0.68 compared to the prior year, despite a higher diluted share count and a one-time EPS gain not repeated in 2025 [6][20] - Free cash flow reached a record $141 million, up 493% from the previous year, with the company returning to debt-free status after paying off nearly $900 million from the NuVasive merger [7][30] - GAAP net income was $75.5 million, translating to fully diluted GAAP earnings of $0.54 per share, an increase from the prior year quarter [20] Business Line Data and Key Metrics Changes - U.S. Spine revenue grew by 2% in Q1, driven by strong retention rates and product cross-selling, despite temporary supply chain disruptions [8][21] - Enabling Technologies revenue decreased by 31% to $22 million, impacted by a tough prior year comparison and elongated selling cycles [12][19] - The combined trauma and NSO business declined by 8%, although core trauma delivered 34% growth [14][21] - International spine implant business grew by 1% on a constant currency basis, affected by timing of distributor orders and supply chain issues [13][21] Market Data and Key Metrics Changes - U.S. revenue was $483.9 million, essentially flat compared to the prior year, while international revenue decreased by 7.7% [26] - The overall market growth was described as slow, with surgeons noting longer approval times from insurance companies [95] Company Strategy and Development Direction - The company aims to focus on sustained profitable growth, leveraging financial strength to accelerate top-line results while maintaining strong EPS and free cash flow [7][8] - The acquisition of Nevro for $250 million is expected to expand the company's reach into the musculoskeletal market, adding a $3 billion market space [14][15] - The company is committed to integrating Nevro into its existing infrastructure to improve profitability and cash flow [15][16] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in recovering from Q1 challenges, citing positive trends in U.S. Spine and ongoing remediation of supply chain issues [45][46] - The company reaffirmed its 2025 net sales guidance of $2.8 billion to $2.9 billion but lowered non-GAAP EPS guidance to $3.0 to $3.3 due to additional costs from the Nevro acquisition [36][37] - Management remains optimistic about the second quarter, expecting to see improved results as supply chain disruptions ease [37][38] Other Important Information - The company has completed its share repurchase program, buying back over 20% of the dilution created from the NuVasive merger [30][31] - The company is actively addressing tariff impacts through cost action offsets, including price increases and vendor negotiations [35][112] Q&A Session Summary Question: Confidence in Q2 performance after a challenging Q1 - Management indicated that supply chain disruptions and timing of distributor orders were temporary issues, with confidence in a recovery in Q2 [45][46] Question: Synergies from the Nevro acquisition - Focus will be on reducing operational expenses and improving gross margins, with a commitment to driving profitable sales growth [48][49] Question: Impact of competitors on sales cycles - Management noted that while selling cycles have elongated, they have not seen competitors causing delays in closing deals [53][54] Question: Expectations for cash use post-Nevro acquisition - The company plans to prioritize internal investments and may consider tuck-in acquisitions, with share repurchases remaining part of the capital structure [62][64] Question: Integration status of Nevro and NuVasive - Management reassured that Nevro's integration is separate from ongoing NuVasive activities, with confidence in managing both integrations effectively [86][88] Question: Update on FDA warning letter - Management reported progress with the FDA and is awaiting inspection, expressing readiness to resolve the matter [92] Question: Impact of tariffs on margins - Management stated that tariffs are not expected to materially impact margins due to the company's vertical integration and U.S.-based production [111][112]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______________ to _______________ Commission File No. 001-35621 GLOBUS MEDICAL, INC. (Exact name of registrant as specified in its charter) DELAWARE 04-3744954 (State or oth ...

Exhibit 99.1 Globus Medical Reports First Quarter 2025 Results AUDUBON, PA, May 8, 2025: Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced its financial results for the quarter ended March 31, 2025. "Our first quarter results were impacted by softer Enabling Technology deal closures, temporary integration related supply chain disruption, and timing of international distributor orders, partially offset by strength in our core US spine business," commented Dan Sca ...

Core Insights - Globus Medical reported a net sales of $598.1 million for Q1 2025, reflecting a decrease of 1.4% compared to Q1 2024, with U.S. sales slightly increasing by 0.2% while international sales decreased by 7.7% [2][9][42] - The company achieved a GAAP net income of $75.5 million, a significant improvement from a loss of $7.1 million in the same period last year, with diluted EPS rising to $0.54 from a loss of $0.05 [3][9][18] - The company reaffirmed its full-year 2025 revenue guidance in the range of $2.80 to $2.90 billion, while adjusting its non-GAAP diluted EPS guidance down to $3.00 to $3.30 from a previous range of $3.10 to $3.40 [5] Financial Performance - The decrease in worldwide net sales was primarily attributed to fewer enabling technology unit sales, with international net sales decreasing by 4.6% on a constant currency basis [2][9][42] - Non-GAAP diluted EPS for Q1 2025 was reported at $0.68, an increase of 8.5% from $0.63 in Q1 2024 [3][9][38] - The company generated a record free cash flow of $141.2 million for the quarter, with net cash provided by operating activities amounting to $177.3 million [4][40] Debt and Cash Management - Globus Medical returned to a debt-free status by paying off the remaining $450 million of debt from the NuVasive merger [2][4] - As of March 31, 2025, the company had cash and cash equivalents of $461.3 million, down from $784.4 million at the end of 2024 [20][28] Product Performance - The musculoskeletal solutions segment generated $575.9 million in sales, while enabling technologies sales were $22.2 million, down from $32.0 million in the previous year [25][9] - The company continues to focus on innovation and investment in advanced products to enhance patient care [2][5]

Core Viewpoint - Wall Street anticipates a year-over-year increase in earnings for Globus Medical, driven by higher revenues, with a focus on how actual results compare to estimates impacting stock price [1][2]. Earnings Expectations - The upcoming earnings report is expected to show quarterly earnings of $0.74 per share, reflecting a +2.8% change year-over-year, with revenues projected at $628.32 million, up 3.6% from the previous year [3]. Estimate Revisions - The consensus EPS estimate has remained unchanged over the last 30 days, indicating a stable outlook from analysts [4]. Earnings Surprise Prediction - The Zacks Earnings ESP model suggests that the Most Accurate Estimate for Globus Medical is higher than the consensus estimate, resulting in a positive Earnings ESP of +2.40%, indicating a bullish sentiment among analysts [10]. Historical Performance - Globus Medical has a strong track record, having beaten consensus EPS estimates in the last four quarters, including a +10.53% surprise in the most recent quarter [12][13]. Stock Ranking - The company currently holds a Zacks Rank of 3, suggesting a likelihood of beating the consensus EPS estimate [11]. Conclusion - Globus Medical is positioned as a compelling candidate for an earnings beat, but investors should consider additional factors beyond earnings expectations when making investment decisions [16].

Core Insights - The first-quarter reporting cycle shows a positive trend with most companies exceeding earnings estimates, although macroeconomic uncertainty is affecting future earnings outlooks [1] - The Medical sector is experiencing significant earnings growth, acting as a buffer against rising market volatility due to increasing tariffs [1][2] Medical Sector Performance - Key medical product companies are recovering from previous cost increases and supply-chain disruptions, with artificial intelligence integration expected to drive medical device adoption in 2025 [2] - At-home medical solutions are projected to continue their growth trend in 2025, despite potential negative impacts from rising tariffs [2] - As of April 30, 45% of Medical sector companies reported quarterly earnings, with 85.2% beating earnings estimates and 70.4% exceeding revenue expectations [3] - Year-over-year earnings in the Medical sector improved by 60.5%, while revenues increased by 7.8% [3] Earnings Expectations - The Medical sector's first-quarter earnings are anticipated to surge by 40%, with sales expected to rise by 8.3% year over year [4] - Hims & Hers Health is projected to report a first-quarter EPS of 14 cents, indicating a 180% growth from the previous year [8] - Globus Medical's first-quarter EPS is estimated at 74 cents, reflecting a 2.8% increase from the prior year [10] - QuidelOrtho's first-quarter EPS is expected to be 60 cents, showing a 36.4% improvement from the year-ago period [11] - Haemonetics is anticipated to report a first-quarter EPS of $1.22, suggesting a 35.6% increase from the previous year [12]

AUDUBON, Pa., April 17, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal technology company, will announce its financial results for the first quarter ended March 31, 2025 after the market close on Thursday, May 8, 2025. A copy of the release will be available on the Globus Medical website at www.investors.globusmedical.com. Following the announcement, Globus Medical will hold a teleconference to discuss its performance with the investment community at 4:30 p.m. Eastern T ...

Company Overview - Globus Medical, Inc. (GMED) has completed the acquisition of Nevro Corp., enhancing its position in the musculoskeletal market [1] - The acquisition is expected to unlock a market opportunity valued at $2.50 billion [4] Financial Performance - Globus Medical has a market capitalization of $9.47 billion, with projected revenues for 2025 expected to increase by 6.5% year over year [3] - Following the acquisition, net sales projections for 2025 are estimated to be between $2.80 billion and $2.90 billion, an increase from previous estimates of $2.66 billion to $2.69 billion [6] Market Trends - The global orthopedic devices market was valued at $59.4 billion in 2023, with a projected compound annual growth rate of 5.3% through 2032, driven by factors such as the rising prevalence of osteoporosis and musculoskeletal diseases [7] Recent Developments - Globus Medical recently launched the COHERE ALIF Spacer, a new product designed for anterior lumbar interbody fusion surgery, along with Modulus ALIF Blades, expanding its product offerings [9] Stock Performance - Since the acquisition announcement on April 3, shares of Globus Medical have decreased by 4.6%, closing at $72.02 [2] - Over the past year, GMED shares have increased by 29.5%, contrasting with an 18.8% decline in the industry [10]

AUDUBON, Pa., April 03, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal technology company, today announced the completion of its previously disclosed acquisition of Nevro Corp., a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain. "We are excited to begin the journey of accelerating market penetration of Nevro's differentiated high-frequency technology and bringing a much-needed treatment option to ...

Globus Medical, Inc. (GMED) continues to benefit from the robust demand for its Musculoskeletal Solutions products. Following the NuVasive merger, the combined company has formed a global musculoskeletal company focused on rapid innovation, addressing unmet clinical needs, and improving offerings to surgeons and patients. Additionally, its string of product launches is highly promising to drive growth in the coming quarters. Meanwhile, headwinds from adverse macroeconomic events and intense competition rema ...